Literature DB >> 33929488

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.

Zoé L E van Kempen1, Eva M M Strijbis1, Marissa M C T Al1, Maurice Steenhuis2, Bernard M J Uitdehaag1, Theo Rispens2, Joep Killestein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33929488      PMCID： PMC8087977          DOI： 10.1001/jamaneurol.2021.1364

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  17 in total

1.  Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

2.  Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2021-11-18       Impact factor: 5.732

3.  Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.

Authors:  Laura Boekel; Maurice Steenhuis; Femke Hooijberg; Yaëlle R Besten; Zoé L E van Kempen; Laura Y Kummer; Koos P J van Dam; Eileen W Stalman; Erik H Vogelzang; Olvi Cristianawati; Sofie Keijzer; Gestur Vidarsson; Alexandre E Voskuyl; Luuk Wieske; Filip Eftimov; Ronald van Vollenhoven; Taco W Kuijpers; S Marieke van Ham; Sander W Tas; Joep Killestein; Maarten Boers; Michael T Nurmohamed; Theo Rispens; Gertjan Wolbink
Journal:  Lancet Rheumatol       Date:  2021-08-06

Review 4.  Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.

Authors:  Peter Rieckmann; Diego Centonze; Gavin Giovannoni; Le H Hua; Celia Oreja-Guevara; Daniel Selchen; Per Soelberg Sørensen; Patrick Vermersch; Heinz Wiendl; Hashem Salloukh; Bassem Yamout
Journal:  Ther Adv Neurol Disord       Date:  2021-12-07       Impact factor: 6.430

5.  Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.

Authors:  Joseph J Sabatino; Kristen Mittl; William M Rowles; Kira McPolin; Jayant V Rajan; Matthew T Laurie; Colin R Zamecnik; Ravi Dandekar; Bonny D Alvarenga; Rita P Loudermilk; Chloe Gerungan; Collin M Spencer; Sharon A Sagan; Danillo G Augusto; Jessa R Alexander; Joseph L DeRisi; Jill A Hollenbach; Michael R Wilson; Scott S Zamvil; Riley Bove
Journal:  JCI Insight       Date:  2022-02-22

6.  Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.

Authors:  Laura Boekel; Femke Hooijberg; Erik H Vogelzang; Yaëlle R Besten; Maureen Leeuw; Sadaf Atiqi; Ronald F van Vollenhoven; Carla A Wijbrandts; Martijn Gerritsen; C Krieckaert; Bas Dijkshoorn; Siham Bakhlakh; Juliette J Crooijmans; Alexandre Voskuyl; Irene E van der Horst-Bruinsma; Willem Lems; Taco W Kuijpers; S Marieke van Ham; Luuk Wieske; Filip Eftimov; Laura Y Kummer; Pj Koos van Dam; Eileen W Stalman; Maurice Steenhuis; Sofie Keijzer; Olvi Cristianawati; Jim Keijser; Floris C Loeff; Sander W Tas; Michael T Nurmohamed; Maarten Boers; Theo Rispens; Gertjan Wolbink
Journal:  RMD Open       Date:  2022-04

7.  Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.

Authors:  Tyler E Smith; Maya Madhavan; Daniel Gratch; Aneek Patel; Valerie Saha; Carrie Sammarco; Zoe Rimler; Guadalupe Zuniga; Dunia Gragui; Leigh Charvet; Gary Cutter; Lauren Krupp; Ilya Kister; Lana Zhovtis Ryerson
Journal:  Mult Scler Relat Disord       Date:  2022-03-11       Impact factor: 4.808

8.  Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Authors:  Hela-Felicitas Petereit; Hayrettin Tumani; Uwe K Zettl
Journal:  Ther Adv Neurol Disord       Date:  2021-06-03       Impact factor: 6.570

9.  Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.

Authors:  Joseph J Sabatino; Kristen Mittl; William Rowles; Kira Mcpolin; Jayant V Rajan; Colin R Zamecnik; Ravi Dandekar; Bonny D Alvarenga; Rita P Loudermilk; Chloe Gerungan; Collin M Spencer; Sharon A Sagan; Danillo G Augusto; Jessa Alexander; Jill A Hollenbach; Michael R Wilson; Scott S Zamvil; Riley Bove
Journal:  medRxiv       Date:  2021-09-20

10.  SARS-CoV-2 antibody seroprevalence in a large neuroimmunological patient cohort.

Authors:  Joachim Havla; Tania Kümpfel; Katharina Eisenhut; Stefan Buchka; Peter Eichhorn; Harald Meier; Fady Albashiti; Ulrich Mansmann; Miriam Schlüter
Journal:  J Neurol       Date:  2021-10-05       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.